Table 1 Demographic characteristics of 7768 patients
Overall | 2004–06 | 2007–09 | 2010–12 | ||
|---|---|---|---|---|---|
n = 7768 (%) | n = 2303 (%) | n = 2449 (%) | N = 3016 (%) | P value | |
Age (years) | |||||
< 60 | 424 (5.5) | 154 (6.7) | 124 (5.1) | 146 (4.8) | |
60–69 | 2438 (31.4) | 68.4 (29.7) | 739 (30.2) | 1015 (33.7) | |
70–79 | 3825 (49.2) | 1117 (48.5) | 1250 (51.0) | 1458 (48.3) | |
≥ 80 | 1081 (13.9) | 348 (15.1) | 336 (13.7) | 397 (13.2) | 0.001 |
PSA at diagnosis | |||||
10.0 or less | 3729 (48.0) | 963 (41.8) | 1160 (47.4) | 1606 (53.2) | |
10.1–20 | 1746 (22.5) | 554 (24.1) | 563 (23.0) | 629 (20.9) | <0.001 |
> 20 | 2293 (29.5) | 786 (34.1) | 726 (29.6) | 781 (25.9) | |
Gleason score | |||||
-6 | 2606 (33.5) | 906 (39.3) | 865 (35.3) | 835 (27.7) | |
7 | 2827 (36.4) | 722 (31.4) | 892 (36.4) | 1213 (40.2) | |
8–10 | 2335 (30.1) | 675 (29.3) | 692 (28.3) | 968 (32.1) | <0.001 |
Clinical T stage | |||||
T1 | 2580 (33.2) | 766 (33.3) | 839 (34.3) | 975 (32.3) | |
T2 | 3260 (42.0) | 933 (40.5) | 986 (40.3) | 1341 (44.5) | |
T3 | 1544 (19.9) | 489 (21.2) | 489 (20.0) | 566 (18.8) | |
T4 | 384 (4.9) | 115 (5.0) | 135 (5.5) | 134 (4.4) | 0.014 |
Clinical N stage | |||||
N0 | 7237 (93.2) | 2161 (93.8) | 2278 (93.0) | 2798 (92.8) | |
N1 | 531 (6.8) | 142 (6.2) | 171 (7.0) | 218 (7.2) | 0.296 |
Clinical M stage | |||||
M0 | 6964 (89.6) | 2019 (87.7) | 2207 (90.1) | 2738 (90.8) | |
M1a | 25 (0.3) | 11 (0.5) | 6 (0.2) | 8 (0.3) | |
M1b | 719 (9.3) | 257 (11.2) | 211 (8.6) | 251 (8.3) | |
M1c | 60 (0.3) | 16 (0.7) | 25 (1.0) | 19 (0.6) | 0.003 |
Risk classification (NCCN) | |||||
Very Low to Low | 1505 (19.4) | 467 (20.3) | 511 (20.9) | 527 (17.5) | |
Intermediate | 2581 (33.2) | 677 (29.4) | 793 (32.4) | 1111 (36.8) | |
High | 2269 (29.2) | 715 (31.0) | 670 (27.4) | 884 (29.3) | |
Locally advanced | 435 (5.6) | 121 (5.3) | 175 (7.1) | 139 (4.6) | |
Metastatic | 978 (12.6) | 323 (14.0) | 300 (12.2) | 355 (11.8) | <0.001 |